S ome people hear voices that are the products only of processes in their brains. These hallucinations can lead to persistent delusions that someone is plotting against them or urging them to harm others. When a person acts on those delusions, headline-grabbing tragedy can ensue, usually involving someone close to the protagonist.
Violence is not a symptom of schizophrenia -only a tiny proportion of sufferers with the condition are homicidal. Yet these incidents dominate the media coverage of the disease. The reality of schizophrenia is much more complex. Hallucinations are one of several symptoms, others of which -cognitive dysfunction, loss of motivation and of social engagement -are much less amenable to medication, and are often more damaging to the ability of those with schizophrenia to function. In recent years it has been increasingly appreciated that this collection of symptoms, which typically first fully manifest in early adulthood, represents a late stage of the illness, and that the illness itself may perhaps turn out to be a collection of syndromes, rather than a single condition.
Motivated by the undue stigma and by the recent advances reported in our own pages and elsewhere, Nature this week examines the state of our understanding of schizophrenia, and how researchers can hope to make progress in an entangled landscape of innate and environmental influences. The image on this issue's cover and in the logo that links the associated content is a piece of art by a schizophrenia sufferers. It is one of many compiled by NARSAD, a US charity based in New York that spends significant public donations on psychiatric health research. The image reflects a world of confusion and distorted reality -but not a 'split personality' , which is a mythical symptom of the condition, and leads to a misleading metaphorical use of the word 'schizophrenic' that those involved with the condition perpetually seek to eradicate.
Globally, somewhere between 0.5% and 1% of the population will experience schizophrenia in their lifetime. It is not the most prevalent psychiatric condition -clinical depression, aka unipolar disorder, is the most common. But analyses by the World Health Organization and others show that it has a disproportionate social cost. Moreover, owing to the few high-profile tragic episodes, it is probably the psychiatric condition with the most stigma attached -a stigma that is persistent, as those who have fought it have discovered time and again (see page 163).
In some societies, schizophrenia is not recognized as a disease -the response to its symptoms can be very dependent on culture, as can the degree of support that sufferers receive. Where it is recognized and treatment is given, it poses some of the greatest challenges in medical care. Drugs that treat the delusional symptoms have been around for decades, and have helped many sufferers enormously. But these drugs have not advanced in effectiveness, and several manufacturers have now backed out of this arena (see page 158). Cognitive and behavioural therapies have also made progress, but they suffer from a lack of coherent research and due priority (see page 165). In the current round of development of clinical diagnostics of the disease, the very definition of schizophrenia is under debate (see page 168).
One of the key diagnostic and scientific challenges is to distinguish the early phases of this condition, using all the means of biological, behavioural and cognitive analyses at our disposal. As with most diseases, the earlier the diagnosis, the greater the ability to mitigate the disease's impact or to defeat it. Recent research indicates that it may be possible to diagnose an 'at-risk' condition at the earliest phases of schizophrenia -for that reason as well as others, studies of adolescent brain development and behaviour have become a crucial research pathway (see pages 154 and 187). More generally, studies of the brain's morphology and circuitry (see page 194), and of the ways in which genetic and environmental influence interact (see page 203), are poised to make substantive progress.
We are in a decade in which fundamental science and clinical and social research can make an enormous impact on mental health (see Nature 463, 9; 2010). Those who have schizophrenia, and their families and colleagues who are also affected by the condition, depend on research to deliver new diagnostics and treatments. The rapid progress in science is daunting in the complexities that it has revealed. But it is yielding much for sufferers to hope for and new paths for researchers to follow. Funders please note. ■ go.nature.com/xhunqv struggling economy. Current law requires the state to cut greenhousegas emissions by 25% on 1990 levels by 2020, and the California Air Resources Board is bringing in regulations to make that happen, including a cap-and-trade system that would allow businesses to decide where to make emissions reductions. California has long led the United States on environmental policy, and this is exactly the kind of action that will expand and could, in time, pave the way for a more comprehensive approach on climate in Washington DC.
California has already been joined by seven other states in the country's west, and four Canadian provinces, in the Western Climate Initiative. Farther east, six states and one Canadian province have signed the Midwestern Greenhouse Gas Reduction Accord. These two programmes aim to cut greenhouse-gas emissions by 15% and 20%, respectively, on 2005 levels by 2020. Carbon trading has already begun under the first such programme, the Regional Greenhouse Gas Initiative, under which ten northeastern states have committed to reducing current levels of emissions by 10% by 2018.
In total, 23 US states and five Canadian provinces have begun their own climate initiatives, independent of their countries' federal governments. The Washington DC-based World Resources Institute calculates that these initiatives cover half the US population and one-third of its greenhouse-gas emissions. In Canada, the numbers are even more impressive: more than three-quarters of the population and half the greenhouse-gas emissions are covered. Twenty-eight states have standards on renewable energy, and countless other efforts are under way that would encourage energy savings and greenhouse-gas reductions at the state and local level.
And do not count out the federal government just yet. The administration of President Barack Obama is preparing to roll out new greenhouse-gas regulations next year and has a variety of other tools at its disposal. The administration has ordered the federal government, the largest energy consumer in the nation, to reduce emissions by 28% on 2008 levels by 2020. The federal government -and the defence department in particular -also has enormous purchasing power. If used wisely, that could help drive green technologies to market. Clearly, these limited efforts are not sufficient. Concerned citizens in the United States and around the world are right to be disappointed in the lack of leadership and vision in Congress. Barring a sharp reversal on their campaign rhetoric, it seems that the situation will only get worse when Republicans take control of the House of Representatives next year. But many of these Republicans hail from those states that are quietly embarking on their own programmes to combat global warming. These aren't just feel-good measures, either. They are confidence builders.
It's possible that, globally, climate change is simply too complex a problem for a comprehensive top-down solution. There are too many interests at stake, too many losers with loud voices. And although most Americans clearly accept the reality of global warming, most people simply don't care that much, particularly when economic woes loom large. That's not a recipe for success in the power corridors of Washington. But California and other US states are policy labs of long standing, and as such will continue to demonstrate the power of 'bottom-up' leadership. ■
Worth waiting for
A wise report on genetic screening from the Leopoldina has been 350 years in the making. T his week, the Leopoldina, Germany's national academy of sciences in Halle, is due to publish a historic report. The publication analyses how advances will affect the field of predictive genetic diagnosis, and calls for changes in a law that has confused science and ideology. It is also notable for being the first report to come from the Leopoldina in its role as a national academy -three and a half centuries after it was set up.
The law, which came into force in February, had been debated for nearly a decade. The legislation was intended to protect the population from the possible abuse of genetics, but instead presents an unreasonable threat to the health of individuals with treatable genetic disorders.
One problem is that the law ranks patient confidentiality above a doctor's responsibility to the health of that patient's relatives. It rules, for example, that genetic data collected for diagnosis should be destroyed after ten years, even though the guidelines of the German Chamber of Physicians say that such data should be retained for at least 30 years to provide for the health of the next generation. The law also misunderstands details of science. To name but one instance, it redefines neonatal screening for genetic disease -used routinely for decades to identify 12 treatable genetic disorders by chemical, not DNA, analysis -as 'genetic screening' . This means that a doctor with expertise in genetic counselling, rather than a midwife, must take blood for the test. This complicates processes, and in small rural hospitals where such expertise is not available some doctors are reportedly simply choosing not to screen.
These problems have their roots in a cultural fear of sharing medical data -a legacy of the Nazi era. With Germany's federalized health-care system, patients can move between doctors of their choosing without any of their medical history following them. This situation makes it impossible to carry out optimal population screening for genetic diseases, and will restrict the future health value of new technologies.
The Leopoldina, too, is embroiled in the legacies of history -and has seen a lot of history flow past since it was founded as a scientific academy in 1652. In 2007, federal research minister Annette Schavan unilaterally declared that the Leopoldina would become Germany's national academy. In doing so, she put an end to years of acrimonious debate about which, if any, of the country's seven regional academies should be elevated to this status. That ruffled feathers. Germany's federal structure was designed as a core element of its 1949 constitution, to prevent any centralization of power and thus to ensure that a fascist regime could never take control again. Individual states were given wide powers and have inevitably become protective of them. All this left Germany without a national academy to provide, among other things, authoritative and independent scientific advice for policymaking. With its first report, the Leopoldina has already shown the value of such an institution.
The academy established a committee of 17 scientists and legal experts to analyse how new genomic technologies and other advances are set to affect predictive genetic diagnosis, and how Germany can better prepare itself for the opportunities and ethical challenges that will follow. The resulting report, Predictive Genetic Diagnostics as an Instrument of Disease Prevention, calls for the creation of national centres of competence to overcome these barriers. There are legal hurdles to this, but they can, and should, be overcome.
The Leopoldina's report responds to a shadow of history. Politicians should follow its recommendations and change the law to prevent further damage. It is time for Germany to see its past in the appropriate historical context, and to ensure that its psychological legacies do not inadvertently harm the innocent today. 
